Small molecule ligands define a binding site on the immune regulatory protein B7.1.
The interaction of co-stimulatory molecules on T cells with B7 molecules on antigen presenting cells plays an important role in the activation of naive T cells. Consequently, agents that disrupt these interactions should have applications in treatment of transplant rejection as well as autoimmune diseases. To this end, specific small molecule inhibitors of human B7.1 were identified and characterized. These compounds inhibit the binding of B7.1 to both CD28 and CTLA4. Both classes of compounds appear to bind the same site, a relatively small portion of the GFCC'C" face of the N-terminal V-set domain of human B7.1, not present in the homologous B7.2 or even mouse B7.1. This site may represent a rare hot spot for small molecule antagonist design of inhibitors of cell-cell interactions, whose ligands may yield leads for the development of novel immunomodulatory medicines.
Erbe
David V
DV
Wyeth Research, Cambridge, Massachusetts 02140, USA.
Wang
Suyue
S
Xing
Yuzhe
Y
Tobin
James F
JF
D000818:Animals; D018122:B7-1 Antigen / Q000737:chemistry* / Q000378:metabolism*; D001665:Binding Sites; D018106:CD28 Antigens / Q000096:biosynthesis / Q000737:chemistry / Q000378:metabolism; D016466:CHO Cells; D002448:Cell Adhesion; D006224:Cricetinae; D004797:Enzyme-Linked Immunosorbent Assay; D006801:Humans; D020128:Inhibitory Concentration 50; D007700:Kinetics; D008024:Ligands; D051379:Mice; D008956:Models, Chemical; D011485:Protein Binding; D017434:Protein Structure, Tertiary; D013997:Time Factors
D018122:B7-1 Antigen; D018106:CD28 Antigens; D008024:Ligands